FcRn Inhibitor Market Outlook: Key Players and Emerging Trends FcRn Inhibitor: Transforming Autoimmune Disease Treatment The therapeutic landscape for autoimmune and rare immune-mediated disorders is undergoing a paradigm shift with the rise of FcRn Inhibitor drugs. These novel agents target the neonatal Fc receptor (FcRn), a key protein responsible for recycling immunoglobulin G (IgG)...

The autoimmune treatment paradigm has been fundamentally transformed through the successful commercialization of Argenx's VYVGART, which achieved the historic milestone of becoming the first FcRn inhibitor to gain regulatory approval and market access. This innovative therapeutic solution has delivered exceptional clinical performance in generalized myasthenia gravis (gMG) management while...